Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
about
Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levelsMolecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsQuantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligandsMultivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostatesMethods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test.A comparative analysis of gene-expression data of multiple cancer types.Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approachThe clinical impact of different assays for prostate specific antigen.The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer.Applicability of biomarkers in the early diagnosis of prostate cancer.A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.The value of screening tests for detection of prostate cancer in 1000 saudi menThe changing scenario in diagnosing prostate cancer.Prostate-specific antigen, sexual behavior, and sexually transmitted infections in US men 40-59 years old, 2001-2004: a cross-sectional study.Prostate cancer markers: An update.Measurement of serum total and free prostate-specific antigen in women with colorectal carcinomaSystematic, evidence-based discovery of biomarkers at the NCI.A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer.The effect of antibiotherapy on prostate-specific antigen levels and prostate biopsy results in patients with levels 2.5 to 10 ng/mL[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.Multi-marker testing for cancer: what can we learn from modern prenatal testing for Trisomy-21.Latest tests for prostatic neoplasia.Immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection.A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients.A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.Prostatic specific antigen for prostate cancer detection.Biomarkers for prostate cancer detection.The influence of prostate volume on the prostate-specific antigen (PSA) level adjusted for the transition zone volume and free-to-total PSA ratio: a prospective study.Addressing the need for repeat prostate biopsy: new technology and approaches.Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).Free prostate-specific antigen 'in the field': a useful adjunct to standard clinical practice.Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma.alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.Should we and can we cure prostate cancer?Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells.
P2860
Q24550631-29EE2D97-CE85-4796-85B7-CC351AE73818Q24629083-E0270C51-A2FA-4DAB-AA23-EA7EAC455B7EQ24655544-EA863446-3482-48CE-AC9C-4D70FAFF2B8CQ33389634-6BCFF340-9C05-4D35-AB60-E3BD483BC817Q33573087-809A2B96-3DF5-4374-9D54-FC00EBBBAD17Q33742162-AD3D3B24-DAA9-42E6-929B-40ACB999DC75Q33770342-B0C712D6-0D35-48D5-A7B1-EAA016BD3C89Q34022442-EAB2D71A-FDA9-4FD4-BFA1-C80785AB607CQ34447102-3AEF26E8-A2F2-4E19-B922-E1C76CCC260AQ34561148-FE27BC26-0B29-42DD-A9C4-4ABD876E9CBEQ34957004-D254D2EE-37D9-4D92-B859-6C79B1A21876Q35821838-70515B87-6C56-485E-A834-91FD14834679Q35995359-510671B7-D3F0-4388-B444-C0DF85EDA649Q36133950-E66AF904-8001-4635-9954-FD442D6FED0EQ36265176-B977254F-DA3A-4E38-BE21-A0C42A833194Q36326720-0DB6A29E-00F8-4711-87A6-1C0A1BFE272FQ36640109-2C259DDB-62C4-47EF-B2AB-3984D59B05FDQ36643689-8E522453-7223-4B40-A6FD-90F11A2B875CQ36922015-8E995254-F365-4171-8B69-8D84143C6E91Q37084150-8DDA5587-E0FA-4103-B673-D29C8107B076Q37089968-383CBD2B-E0C1-4B54-97A7-AF1B3232D674Q37108081-0BA73358-CEDF-4B9D-A7E8-11AD39081147Q37175042-453E9029-9576-460A-966C-7510EA9E310DQ37222117-51F5EA7C-9058-4CAD-9A19-0729263BC4A5Q37411585-26AD6CD0-A152-4DF1-A36D-14B0E86D67E9Q37485613-F22D518A-44CC-4191-B414-26FCBC777B8CQ37507776-869706D7-7D84-43E7-BA30-8C30F2F52BF4Q37622491-2D4CD42C-E843-42E0-88B0-80986E4467FFQ37656233-6E93EF5D-8300-4609-AB69-53DC1166BCCFQ38525737-E49369EA-856B-42E3-AD7B-7F9A168DC55DQ38546671-AD94284C-8F5A-4B8E-BE47-0C2B37AEC406Q39023692-5CC00382-C83A-4AD5-9752-F2100D2FE3E0Q39510461-372E775A-12D9-4ECE-92D7-6AEC27BE70A8Q39534052-8147591C-8016-42E0-ADC9-6C4D207F11B8Q39534061-4C3C76BF-5067-48B3-841C-350827DFC17CQ39544983-1C615384-FBFB-4416-B73E-6E8DBF0465D5Q39763616-242D52B0-989D-4A9E-8739-072AF6749070Q39811058-7DD87B51-3ECE-4EF7-904D-27FB3ABB97B7Q40257803-96974B0A-C02F-40C0-86FF-6722521B3130Q40866956-51947E90-62B2-4E36-8265-5A932BE03D07
P2860
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Evaluation of percentage of fr ...... of prostate cancer screening.
@en
Evaluation of percentage of fr ...... of prostate cancer screening.
@nl
type
label
Evaluation of percentage of fr ...... of prostate cancer screening.
@en
Evaluation of percentage of fr ...... of prostate cancer screening.
@nl
prefLabel
Evaluation of percentage of fr ...... of prostate cancer screening.
@en
Evaluation of percentage of fr ...... of prostate cancer screening.
@nl
P2093
P1476
Evaluation of percentage of fr ...... of prostate cancer screening.
@en
P2093
H G Rittenhouse
R B Nadler
R L Wolfert
T L Ratliff
W J Catalona
P304
P356
10.1001/JAMA.1995.03530150038031
P407
P577
1995-10-01T00:00:00Z